ArticleEuropean heart journal2021

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.

Javed Butler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.